Comparison of IV Nalbuphine Versus Ibuprofen for Postoperative Pain Control in Cesarean Section

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The local data is insufficient to directly compare IV nalbuphine versus ibuprofen among people in this region. The findings of this study would add to the existing data and would be helpful for health providers to opt for a better option for postoperative pain relief following a cesarean section under general anesthesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section

NCT02716129

Postoperative Pain

COMPLETED PHASE2

Analgesia Effects of Nalbuphine vs Sulfentanil

NCT02604797

C.Delivery; Surgery (Previous), Gynecological

UNKNOWN NA

Comparison of Morphine With Nalbuphine in a Multimodal Approach for Pain Relief in Patients Undergoing Gynecological Procedures: Randomized Controlled Double Blind Clinical Trial

NCT06191770

Pain, Acute

COMPLETED NA

Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies

NCT07102641

Cesarean Delivery Postpartum Comfort Postpartum Pain +3 more

RECRUITING PHASE4

Tramadol and Tramadol Plus Ketamine for Shivering Prevention After Spinal Anesthesia in Lower Segment Caeserian Section

NCT06134895

Shivering

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Management

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IV Ibuprofen Group

Females in this group (n=40) were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward

Group Type EXPERIMENTAL

Ibuprofen

Intervention Type DRUG

Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.

IV Nalbuphine

Patients in this group received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.

Group Type EXPERIMENTAL

Nalbuphine

Intervention Type DRUG

Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibuprofen

Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.

Intervention Type DRUG

Nalbuphine

Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parturient females
* Aged between 18-45 years
* Gestational age above 32 weeks
* ASA class I to II
* Anticipated hospital stay for at least 24 hours

Exclusion Criteria

* Known allergy to the drugs being evaluated in this study
* Renal and/or hepatic impairment (as per medical record)
* History of bronchial asthma or history or risk of intracranial hemorrhage (as per medical record)
* Low platelets count (\<70000) or with bleeding diathesis
* BMI above 30 kg/m2

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No